A Randomized Phase II Study of Pembrolizumab an anti-PD (programmed cell death)-1 Antibody in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
K
Kathy Miller, MD
Primary Investigator
Overview
This study is being done to see what effects the combination of pembrolizumab and carboplatin have on breast cancer compared to carboplatin alone.
Description
The primary objective is to determine the disease control rate (including CR, PR and stable disease as defined by RECIST 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin or carboplatin alone.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer,chest wall disease
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Advanced breast cancer with locally recurrent chest wall disease not amenable to surgical excision.
- At least two weeks from last systemic therapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or less. Subjects with ≤ Grade 2 neuropathy are an exception to this criterion.
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:Participants will not be paid for their participation.
Updated on
26 Apr 2024.
Study ID: TBCRC044, 1802063021 (TBCRC044), TX8819